Dangerous Drug Interaction: ACE Inhibitors-Potassium Supplements
benazepril (Lotensin)
captopril (Capoten)
enalapril (Vasotec)
fosinopril (Monopril)
lisinopril (Prinivil, Zestril)
moexipril (Univasc)
perindopril (Aceon)
quinapril (Accupril)
ramipril (Altace)
trandolapril (Mavik) |
potassium acetate/potassium bicarbonate/potassium citrate (Tri-K)
potassium acid phosphate (K-Phos)
potassium bicarbonate (K + Care ET)
potassium bicarbonate/potassium citrate (Effer-K, Effervescent Potassium, Klor-Con/EF, K*Lyte)
potassium bicarbonate/potassium citrate/citric acid (K*Lyte DS)
potassium chloride (Cena-K, Gen-K, K+8, K+10, K+Care, K-Dur 10, K-Dur 20, K-Lease, K-Lor, K-Norm, Kaochlor 10%, Kaochlor S-F, Kaon-Cl 20%, Kaon Cl-10, Kay Ciel, Klor-Con, Klor-Con 8, Klor-Con 10, Klor-Con/25, K*Lyte/Cl, Klotrix, K-Tab, K-vescent Potassium Chloride, Micro-K Extencaps, Micro-K 10 Extencaps, Micro-K LS, Potasalan, Rum-K, Slow-K, Ten-K)
potassium chloride/potassium bicarbonate/lysine hydrochloride (Klorvess)
potassium chloride/potassium bicarbonate/potassium citrate/lysine hydrochloride (Klorvess Effervescent Granules)
potassium chloride/potassium bicarbonate/l-lysine monohydrochloride/citric acid (K*Lyte/Cl, K*Lyte/Cl 50)
potassium citrate (Urocit-K)
potassium gluconate (Kaon, Kaylixir)
potassium gluconate/potassium citrate (Twin-K)
potassium gluconate/potassium chloride (Kolyum) |
| Brand names appear in parentheses above and are trademarks of their respective manufacturers/owners. |
Impact: Potential for elevated serum potassium levels.1
Mechanism of Interaction: Inhibition of ACE results in decreased aldosterone production and potentially decreased potassium excretion.
Alternatives to Patient Management: Draw potassium level prior to initiation of ACE-inhibitor in a patient.
Monitoring/Precautions: Potassium levels greater than 5.0 mmol/L should be monitored carefully due to risk of severe hyperkalemia and EKG changes. Watch renal function (BUN, SCr) also. Adjust potassium supplementation if levels increase.
References: Follow this link for a complete list of references.
The above information serves only as a guide for use by qualified medical practitioners in understanding, handling and avoiding frequent and potentially dangerous drug interactions that occur in long-term care. This presentation is not intended to instruct a practitioner how to treat any medical condition, nor is it intended to replace a practitioner's best clinical judgment. AMDA expressly disclaims responsibility and liability for any adverse effects, damages or other consequences resulting from the use of any of the information contained in this presentation.
|